Oncotelic Therapeutics Implements PDAOAI Platform

Posted: January 2, 2025 at 2:44 am

AGOURA HILLS, Calif., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), today announced the implementation of its artificial intelligence (AI) platform PDAOAI. The platform is designed to streamline document search and analysis, to address the growing needs of knowledge-based industries including pharmaceutical and biotechnology. We have been enhancing the capabilities of the platform over the past one year. The platform will be accessible via PDAO tokens, which the Company initially released to eligible shareholders in 2023.

Read more:
Oncotelic Therapeutics Implements PDAOAI Platform

Related Posts